ADIPOQ and metabolic syndrome: Circulating levels of leptin increase during ADT use, with or in the absence of increased fat deposition.50 The actions of adiponectin generally oppose those of leptin such that reductions in adiponectin levels are observed with obesity, type 2 diabetes, CVD, hypertension and MetS.